Biotech Amgen will grow its oncology treatment options with the acquistion of UK-based Dark Blue Therapeutics.

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

PharmAla Australia worked diligently, executing a global RFP search to find our ideal partner for process development and manufacturing of the ALA-002 drug product components,” said Nick Kadysh, ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Josh is the Global Real Estate transaction lead for GSK, focusing on aligning real estate strategies with business objectives and transforming the portfolio to create the World’s healthiest workplaces ...

SAN FRANCISCO—The UK government will embrace an advisory committee's ambitious recommendations for boosting public financing and incentives for biotechnology development, science minister David ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...